Cellular immunotherapy is revolutionizing cancer treatment. However, autologous transplants are complex, costly, and limited by the number and quality of T cells that can be isolated from and expanded for re-infusion into each patient.
This paper demonstrates a stromal support cell-free in vitro method for the differentiation of T cells from umbilical cord blood hematopoietic stem cells (HSCs).
From autologous cancer killers to off-the-shelf products targeting solid tumours like ovarian, prostate and breast cancer, Cartherics is developing them all.
The potential of such therapies is the reason Cartherics’ Chief Scientific Officer Richard Boyd was invited to speak at the international Multi-Functional Cell Therapies Summit in Boston, 4-6 May 2021.
In his presentation, Richard updated delegates on Cartherics’ recent advances.
Natural killer (NK) cells are potent innate immune system effector lymphocytes armed with multiple mechanisms for killing cancer cells. Given the dynamic roles of NK cells in tumor surveillance, they are fast becoming a next-generation tool for adoptive immunotherapy. Many strategies are being employed to increase their number and improve their ability to overcome cancer resistance and the immunosuppressive tumor microenvironment.
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of the nominal epitope.
https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00002-4
Off-the-shelf iPSC derived CAR-NK immunotherapy for solid tumors
Principal Scientist Dr Nicholas Boyd
The clinical impact of Chimeric Antigen Receptor T cell (CAR-T) technologies on hematological malignancies have revolutionized cancer treatment.
However, current autologous CAR-T therapies face major roadblocks for mass adoption.
Despite progress in developing cell therapies, such as T cell or stemcell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application.
Given the fact that a host’s immune system may reject allogeneic transplanted cells, methods have been developed to genetically modify patients’primary cells.
In October 2019 Cartherics attended the prestigious Cell & Gene Meeting on the Mesa https://www.meetingonthemesa.com/ in Carlsbad, California.
Cartherics Chief Scientific Officer, Richard Boyd, presented details to delegates of Cartherics’ pre-clinical in vitro and animal model research, cell manufacture for clinical trials, and corporate game plan.